Research programme: anticancer antibodies - Gigagen
Latest Information Update: 23 Jun 2023
At a glance
- Originator GigaGen
- Developer GigaGen; Unknown
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 18 Apr 2023 GigaGen has patent protection for the Surge technology platform in USA and Europe (GigaGen website, April 2023)
- 18 Apr 2023 Early research in Cancer in USA (Parenteral), prior to April 2023 (Gigagen pipeline, April 2023)